Accumetrics' new CEO to advance commercialization of blood platelet analysis

OCTOBER 31, 2008 -- Accumetrics Inc. (San Diego, CA) has named Timothy I. Still as its new Chief Executive Officer. Mr. Still has served as Accumetrics' President and COO since earlier this year. His commercialization expertise and diagnostic market experience will help the company bring to market its VerifyNow system, which aims to help doctors assess response to antiplatet therapy for patients at risk for cardiovascular disease.

OCTOBER 31, 2008 -- Accumetrics Inc. (San Diego, CA), developer of technology to help doctors assess response to antiplatet therapy for patients at risk for cardiovascular disease, has named Timothy I. Still as its new Chief Executive Officer (CEO). Mr. Still has been serving in the capacity of President and Chief Operating Officer for the company since earlier this year.

"Tim has the right combination of industry, management, and startup experience for our Board," says Tony Arnerich, General Partner of Arnerich & Massena and Executive Chairman of the Board at Accumetrics, "His commercialization expertise and diagnostic market experience will be invaluable as we build key partnerships and move forward with the commercialization of our technology."

Accumetrics' products aim to advance medical understanding of platelet function and enhance quality of care for patients receiving antiplatelet therapies. The company says its VerifyNow system is "the first simple and rapid system for measuring the individual response to multiple antiplatelet agents." VerifyNow measures platelet function by the rate and extent of light changes in whole blood as platelets aggregate over time in response to agonists that are specific to various antiplatelet medications. Within the assay device wells, the instrument measures the increase in light transmittance over time. A patient's blood sample that exhibits inhibited platelet function produces low light transmittance; whereas a sample with normal platelet function produces high light transmittance. The measurement is based on principles of optical aggregometry and has shown to correlate well to that method.

Still's background includes over 18 years of sales, marketing and business development experience in healthcare and medical diagnostics. He has extensive experience in designing and implementing highly focused sales and marketing strategies within both large and small companies.

Prior to Accumetrics, Still was Executive Vice President and Chief Commercial Officer for HemoSense, a medical diagnostic company located in San Jose, California. He was instrumental in building HemoSense into a rapidly growing, publicly traded company (AMEX: HEM) which was acquired by Inverness Medical in November 2007. Before joining HemoSense, Still served as Vice President of Sales and Marketing for Cholestech Corporation, and served in a variety of sales, marketing and business development roles for Boehringer Mannheim Corporation (now Roche Diagnostics).

More information:
Accumetrics Inc.

More in Home